{Reference Type}: Journal Article
{Title}: Retinopathy secondary to multiple myeloma treated with bevacizumab.
{Author}: Salcedo Mafla E;Gutiérrez Benítez L;Asaad M;
{Journal}: Arch Soc Esp Oftalmol (Engl Ed)
{Volume}: 95
{Issue}: 10
{Year}: Oct 2020
暂无{DOI}: 10.1016/j.oftal.2020.05.008
{Abstract}: The case is presented on an 80-year-old woman with IgA multiple myeloma (MM), who developed retinal changes similar to mild non-proliferative diabetic retinopathy, with micro-aneurysms and intraretinal fluid. The patient was treated with systemic chemotherapy for MM, and with bevacizumab intravitreal injections, with control of her ocular disorder for 22 months. Anti-angiogenic therapy can be useful in the control of retinopathy secondary to MM, as long as the systemic disease has been controlled.